Prompted by these results, we wanted to address whether E15.5 CGNPs are sensitive to treatment with the SMO inhibitor cyclopamine, derivatives of which are being used in the treatment of relapsed SHH medulloblastoma (Taipale et al., 2000). This evidence concerns the gene SMO and medulloblastoma.